Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 0.35
NAS:ELGX's Cash to Debt is ranked lower than
75% of the 188 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.37 vs. NAS:ELGX: 0.35 )
Ranked among companies with meaningful Cash to Debt only.
NAS:ELGX' s Cash to Debt Range Over the Past 10 Years
Min: 0.35  Med: No Debt Max: No Debt
Current: 0.35
Equity to Asset 0.35
NAS:ELGX's Equity to Asset is ranked lower than
79% of the 184 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.58 vs. NAS:ELGX: 0.35 )
Ranked among companies with meaningful Equity to Asset only.
NAS:ELGX' s Equity to Asset Range Over the Past 10 Years
Min: 0.31  Med: 0.85 Max: 0.96
Current: 0.35
0.31
0.96
F-Score: 2
Z-Score: -0.72
M-Score: -2.32
WACC vs ROIC
4.99%
-47.49%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -51.24
NAS:ELGX's Operating margin (%) is ranked lower than
80% of the 187 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.66 vs. NAS:ELGX: -51.24 )
Ranked among companies with meaningful Operating margin (%) only.
NAS:ELGX' s Operating margin (%) Range Over the Past 10 Years
Min: -126.68  Med: -21.37 Max: -4.47
Current: -51.24
-126.68
-4.47
Net-margin (%) -78.53
NAS:ELGX's Net-margin (%) is ranked lower than
82% of the 187 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.06 vs. NAS:ELGX: -78.53 )
Ranked among companies with meaningful Net-margin (%) only.
NAS:ELGX' s Net-margin (%) Range Over the Past 10 Years
Min: -119.57  Med: -32.34 Max: 15.84
Current: -78.53
-119.57
15.84
ROE (%) -117.84
NAS:ELGX's ROE (%) is ranked lower than
93% of the 180 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.17 vs. NAS:ELGX: -117.84 )
Ranked among companies with meaningful ROE (%) only.
NAS:ELGX' s ROE (%) Range Over the Past 10 Years
Min: -117.84  Med: -35.43 Max: 15.58
Current: -117.84
-117.84
15.58
ROA (%) -41.66
NAS:ELGX's ROA (%) is ranked lower than
82% of the 190 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.57 vs. NAS:ELGX: -41.66 )
Ranked among companies with meaningful ROA (%) only.
NAS:ELGX' s ROA (%) Range Over the Past 10 Years
Min: -41.66  Med: -19.49 Max: 11.48
Current: -41.66
-41.66
11.48
ROC (Joel Greenblatt) (%) -290.31
NAS:ELGX's ROC (Joel Greenblatt) (%) is ranked lower than
84% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.16 vs. NAS:ELGX: -290.31 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NAS:ELGX' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -290.31  Med: -105.62 Max: -21.18
Current: -290.31
-290.31
-21.18
Revenue Growth (3Y)(%) 8.60
NAS:ELGX's Revenue Growth (3Y)(%) is ranked higher than
68% of the 151 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.00 vs. NAS:ELGX: 8.60 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NAS:ELGX' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -41.3  Med: 15.1 Max: 68.4
Current: 8.6
-41.3
68.4
EBITDA Growth (3Y)(%) 7.40
NAS:ELGX's EBITDA Growth (3Y)(%) is ranked higher than
56% of the 126 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.80 vs. NAS:ELGX: 7.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NAS:ELGX' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -51.1  Med: -6.7 Max: 77.9
Current: 7.4
-51.1
77.9
EPS Growth (3Y)(%) 7.70
NAS:ELGX's EPS Growth (3Y)(%) is ranked higher than
55% of the 121 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.50 vs. NAS:ELGX: 7.70 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NAS:ELGX' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -51.6  Med: 4.1 Max: 128.9
Current: 7.7
-51.6
128.9
GuruFocus has detected 3 Warning Signs with Endologix Inc $NAS:ELGX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:ELGX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q4 2015

ELGX Guru Trades in Q4 2015

Pioneer Investments 843,312 sh (+5.25%)
Paul Tudor Jones Sold Out
Steven Cohen Sold Out
» More
Q1 2016

ELGX Guru Trades in Q1 2016

Paul Tudor Jones 20,724 sh (New)
Jim Simons 341,622 sh (New)
Pioneer Investments 720,793 sh (-14.53%)
» More
Q2 2016

ELGX Guru Trades in Q2 2016

Columbia Wanger 1,149,943 sh (New)
Paul Tudor Jones 26,571 sh (+28.21%)
Pioneer Investments 719,624 sh (-0.16%)
Jim Simons 79,322 sh (-76.78%)
» More
Q3 2016

ELGX Guru Trades in Q3 2016

Jim Simons 288,722 sh (+263.99%)
Pioneer Investments 962,869 sh (+33.80%)
Paul Tudor Jones Sold Out
Columbia Wanger 1,122,185 sh (-2.41%)
» More
» Details

Insider Trades

Latest Guru Trades with ELGX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies    NAICS: 339112    SIC: 3841
Compare:NAS:ATRC, NAS:OSUR, NAS:LMAT, NAS:NVCR, OTCPK:NNCSF, NAS:MLAB, NAS:STAA, NAS:ANGO, NAS:IRTC, NAS:CFMS, NAS:ENTL, NAS:ATRS, NAS:UTMD, NAS:ATRI, AMEX:TRXC, NAS:LMNX, NAS:MBOT, NAS:SIEN, NAS:DSCI, NAS:IVTY » details
Traded in other countries:RM1.Germany,
Endologix Inc develops, manufactures, markets & sells medical devices for the treatment of aortic disorders. Its EVAR products include the Endologix AFX Endovascular AAA System (AFX) and the Endologix Powerlink with Intuitrak Delivery System.

Endologix Inc was incorporated in California on March 16, 1992 under the name Cardiovascular Dynamics, Inc. and reincorporated in Delaware in June 1993. The Company develops, manufactures, markets and sells medical devices for the treatment of abdominal aortic aneurysms (AAA). Its main products are intended for the treatment of AAA through minimally-invasive endovascular repair (EVAR) or endovascular sealing ('EVAS'), solution for sealing the aneurysm sac while maintaining blood flow through two blood flow lumens. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The Company's EVAR products consist of: a cobalt chromium alloy stent covered by polytetrafluoroethylene graft material; and an accompanying delivery system. The Company's EVAS product consists of: bilateral covered stents with endobags; a biocompatible polymer injected into the endobags to seal the aneurysm; and a delivery system and polymer dispenser. Its main competitors include: Medtronic, Inc., W.L. Gore Inc., and Cook Medical Products, Inc., and new market entrants, TrvVascular, Inc. and Lombard Medical Technologies. The Company is subject to additional licensing and regulatory requirements relating to safe working conditions, manufacturing practices, environmental protection, fire hazard control, and disposal of hazardous or potentially hazardous substances.

Ratios

vs
industry
vs
history
P/B 3.67
ELGX's P/B is ranked lower than
62% of the 177 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.28 vs. ELGX: 3.67 )
Ranked among companies with meaningful P/B only.
ELGX' s P/B Range Over the Past 10 Years
Min: 1.69  Med: 5.95 Max: 14.18
Current: 3.67
1.69
14.18
P/S 2.52
ELGX's P/S is ranked higher than
51% of the 180 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.84 vs. ELGX: 2.52 )
Ranked among companies with meaningful P/S only.
ELGX' s P/S Range Over the Past 10 Years
Min: 1.14  Med: 6.06 Max: 20.16
Current: 2.52
1.14
20.16
Current Ratio 2.47
ELGX's Current Ratio is ranked higher than
51% of the 186 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.44 vs. ELGX: 2.47 )
Ranked among companies with meaningful Current Ratio only.
ELGX' s Current Ratio Range Over the Past 10 Years
Min: 2.15  Med: 5.79 Max: 20.25
Current: 2.47
2.15
20.25
Quick Ratio 1.75
ELGX's Quick Ratio is ranked higher than
54% of the 186 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.64 vs. ELGX: 1.75 )
Ranked among companies with meaningful Quick Ratio only.
ELGX' s Quick Ratio Range Over the Past 10 Years
Min: 1.75  Med: 4.58 Max: 19.04
Current: 1.75
1.75
19.04
Days Inventory 208.23
ELGX's Days Inventory is ranked lower than
79% of the 173 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 123.20 vs. ELGX: 208.23 )
Ranked among companies with meaningful Days Inventory only.
ELGX' s Days Inventory Range Over the Past 10 Years
Min: 168.66  Med: 239.82 Max: 482.28
Current: 208.23
168.66
482.28
Days Sales Outstanding 73.82
ELGX's Days Sales Outstanding is ranked lower than
71% of the 153 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 62.71 vs. ELGX: 73.82 )
Ranked among companies with meaningful Days Sales Outstanding only.
ELGX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 58.06  Med: 67.04 Max: 77.86
Current: 73.82
58.06
77.86
Days Payable 71.03
ELGX's Days Payable is ranked higher than
63% of the 144 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 47.06 vs. ELGX: 71.03 )
Ranked among companies with meaningful Days Payable only.
ELGX' s Days Payable Range Over the Past 10 Years
Min: 69.82  Med: 123.89 Max: 288.83
Current: 71.03
69.82
288.83

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -2.80
ELGX's 3-Year Average Share Buyback Ratio is ranked higher than
50% of the 123 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: -2.70 vs. ELGX: -2.80 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ELGX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -35.1  Med: -9.9 Max: -2.8
Current: -2.8
-35.1
-2.8

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.42
ELGX's Price/Median PS Value is ranked higher than
88% of the 155 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.09 vs. ELGX: 0.42 )
Ranked among companies with meaningful Price/Median PS Value only.
ELGX' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.23  Med: 1.1 Max: 8.35
Current: 0.42
0.23
8.35
Earnings Yield (Greenblatt) (%) -22.98
ELGX's Earnings Yield (Greenblatt) (%) is ranked lower than
87% of the 187 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.50 vs. ELGX: -22.98 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ELGX' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -27.01  Med: 0 Max: 0
Current: -22.98
-27.01
0

More Statistics

Revenue (TTM) (Mil) $184.7
EPS (TTM) $ -1.84
Beta0.33
Short Percentage of Float20.18%
52-Week Range $4.78 - 14.50
Shares Outstanding (Mil)82.69

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 197 204 229
EPS ($) -0.74 -0.62 -0.35
EPS w/o NRI ($) -0.74 -0.62 -0.35
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for ELGX

Headlines

Articles On GuruFocus.com
Meridian Funds Comments on Endologix Inc Dec 17 2014 
Meridian Contrarian Fund 3Q 2014 Commentary Dec 17 2014 
Weekly CFO Sells Highlight: ELGX, LOW, NWS, SBUX, WLP Dec 18 2012 
Endologix Inc Reports Operating Results (10-K) Mar 16 2011 
Endologix Inc Reports Operating Results (10-Q) Nov 08 2010 
Weekly CFO Buys Highlight: FCTOA, GNBT, CTTC, ELGX, ARTC Nov 06 2010 
Endologix Inc Reports Operating Results (10-Q) Jul 30 2010 
Weekly CEO Sells Highlight: Cisco Systems Inc, AmerisourceBergen Corp, PAETEC HOLDING CORP, Endologi May 22 2010 
Endologix Inc (ELGX) CEO John D Mcdermott sells 225,000 Shares May 17 2010 
Endologix Inc Reports Operating Results (10-Q) May 10 2010 

More From Other Websites
IMPORTANT EQUITY ALERT: Khang & Khang LLP Announces an Investigation of Endologix, Inc. and... Jan 20 2017
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in... Jan 20 2017
IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces an Investigation of Endologix, Inc. and... Jan 20 2017
The Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of... Jan 20 2017
IMPORTANT INVESTOR ALERT: Goldberg Law PC Announces a Class Action Lawsuit Against Endologix, Inc.... Jan 19 2017
INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Endologix, Inc. of a Class Action... Jan 19 2017
EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Endologix,... Jan 18 2017
IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces an Investigation of Endologix, Inc. and... Jan 18 2017
INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From... Jan 17 2017
IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces an Investigation of Endologix, Inc. and Advises... Jan 17 2017
Endologix Resumes Shipments of All Sizes of AFX®2 Endovascular AAA Systems Jan 17 2017
SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against... Jan 17 2017
IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces an Investigation of Endologix, Inc. and... Jan 12 2017
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Endologix, Inc.... Jan 11 2017
INVESTOR ALERT: Lundin Law PC Announces an Investigation of Endologix, Inc. and Advises Investors... Jan 11 2017
Glancy Prongay & Murray Announces the Filing of a Securities Class Action on Behalf of Endologix,... Jan 11 2017
IMPORTANT INVESTOR ALERT: Goldberg Law PC Announces a Class Action Lawsuit Against Endologix Inc.... Jan 10 2017
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against... Jan 10 2017
IMPORTANT Endologix, Inc. INVESTOR ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a... Jan 09 2017
Robbins Arroyo LLP: Endologix, Inc. (ELGX) Misled Shareholders According to a Recently Filed Class... Jan 09 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)